CC
PYXS icon

Centiva Capital’s Pyxis Oncology PYXS Stock Holding History

Centiva Capital’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,546
Closed -$34.7K – 2013
2023
Q2 		$34.7K Buy
+13,546
New +$43K ﹤0.01% 1521

Other funds holding PYXS

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Centiva Capital's PYXS Position: Q3 2023 in Review

Centiva Capital sold out of Pyxis Oncology (PYXS) in Q3 2023, closing a stake of 13,546 shares — an estimated $34.7K sold.

Centiva Capital first reported a position in PYXS in Q2 2023 and held it in 1 quarter. The position peaked at $34.7K in Q2 2023. 54 funds tracked by Wall St. Rank hold PYXS as of Q3 2023.

  • Centiva Capital reported no remaining Pyxis Oncology position as of Q3 2023 after selling out during the quarter.
  • Centiva Capital sold 13,546 Pyxis Oncology shares in Q3 2023, an estimated $34.7K.
  • Centiva Capital first reported a position in Pyxis Oncology in Q2 2023 and held it in 1 quarter.
  • Centiva Capital's Pyxis Oncology position peaked at $34.7K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.